Inhalation of natural products against lung infections
Disciplines
Biology (25%); Medical-Theoretical Sciences, Pharmacy (75%)
Keywords
- Acute Respiratory Infection,
- Natural Products,
- Anti-Infectives,
- Inhalation Biopharmaceutical Classification System,
- Pulmonary Pharmacokinetics
Most lung infections are viral (such as COVID-19) or bacterial in nature. Currently there are few treatment options for viral infections. Bacterial infections can be treated with available antibiotics but the development of resistance to these treatments is always a concern. Natural products, such as plants and fungi, contain a wealth of antiviral or antibacterial compounds just waiting to be discovered. However, not all of these active compounds retain their efficacy when administered as a tablet or capsule. In these cases, the inhalation of anti-infective drugs offers a promising alternative. Inhalers, like the ones used for asthma treatments, can deliver the drugs directly to the site of infection in the lung, sometimes at much higher concentrations. This can greatly improve the treatment success rate. In our project, we are testing whether newly discovered compounds from natural products, will benefit from an inhalation therapy option. The results of our study will contribute to expanding the treatment options for patients suffering from acute lung infections.
Lung infections can be caused by either viruses (such as COVID-19) or bacteria. Currently, there is only a limited selection of effective medications for viral lung infections. Natural products such as plants and fungi are often sources of multipotent active ingredients, although not all of these substances are effective when administered orally. Inhalation offers a promising approach for treating lung infections. Inhalers used in the treatment of asthma can also be used for infectious diseases. Ideally, inhaling anti-infectives leads to higher drug concentrations in the lungs, allowing for targeted treatment of the infection. In our project, we investigated novel active ingredients from nature and demonstrated that inhalation administration of these substances could offer therapeutic advantages. The results of this study contribute to expanding the therapeutic options for acute lung infections through the use of natural products.
- Universität Wien - 100%
- Johannes Kirchmair, Universität Wien , national collaboration partner
- Judith Maria Rollinger, Universität Wien , national collaboration partner
- Richard D. Harvey, Universität Wien , national collaboration partner
- Michaela Schmidtke, Klinikum der Friedrich-Schiller-Universität Jena - Germany
- Forbes Ben, King´s College London
Research Output
- 60 Citations
- 9 Publications
- 1 Methods & Materials
- 1 Fundings
-
2025
Title Pulmonary delivery of anti-infectives from natural sources: Development and characterization of liposomal sanggenon formulations DOI 10.1016/j.ejps.2025.107361 Type Journal Article Author Schwarzinger J Journal European Journal of Pharmaceutical Sciences Pages 107361 Link Publication -
2025
Title Effects of orally applied sanggenons C and D in BALB/c mice DOI 10.1016/j.phytol.2025.103559 Type Journal Article Author Langeder J Journal Phytochemistry Letters Pages 103559 -
2025
Title Biochemometric 2D NMR-Based Heterocovariance Analysis: A Targeted Approach for Identifying Bioactive Compounds in Complex Mixtures DOI 10.1021/acs.analchem.5c02419 Type Journal Article Author Adelsberger S Journal Analytical Chemistry Pages 22508-22517 Link Publication -
2024
Title Biopharmaceutical profiling of anti-infective sanggenons from Morus alba root bark for inhalation administration DOI 10.1016/j.ijpx.2024.100272 Type Journal Article Author Schwarzinger J Journal International Journal of Pharmaceutics: X Pages 100272 Link Publication -
2025
Title Biochemometrics and biopharmaceutical profiling in drug discovery from natural sources Type PhD Thesis Author Sigrid Adelsberger Link Publication -
2023
Title Correlation of bioactive marker compounds of an orally applied Morus alba root bark extract with toxicity and efficacy in BALB/c mice DOI 10.3389/fphar.2023.1193118 Type Journal Article Author Langeder J Journal Frontiers in Pharmacology Pages 1193118 Link Publication -
2023
Title Molecular networking unveils anti-SARS-CoV-2 constituents from traditionally used remedies DOI 10.1016/j.jep.2023.117206 Type Journal Article Author Wasilewicz A Journal Journal of Ethnopharmacology Pages 117206 -
2023
Title Identification of Natural Products Inhibiting SARS-CoV-2 by Targeting Viral Proteases: A Combined in Silico and in Vitro Approach DOI 10.1021/acs.jnatprod.2c00843 Type Journal Article Author Wasilewicz A Journal Journal of Natural Products Pages 264-275 Link Publication -
2023
Title Discovery of anti-SARS-CoV-2 secondary metabolites from the heartwood of Pterocarpus santalinus using multi-informative molecular networking DOI 10.3389/fmolb.2023.1202394 Type Journal Article Author Wasilewicz A Journal Frontiers in Molecular Biosciences Pages 1202394 Link Publication
-
2025
Title Biochemometric 2D NMR-Based Heterocovariance Analysis DOI 10.1021/acs.analchem.5c02419 Type Technology assay or reagent Public Access
-
2025
Title Anti-Infectives Drug Discovery Type Research grant (including intramural programme) DOI 10.55776/doc3579124 Start of Funding 2025 Funder Austrian Science Fund (FWF) Department of Pharmaceutical Sciences